The Fruhwirth Lab

Through a great team effort we demonstrated quantitative non-invasive Treg tracking over weeks.

This addressed a fundamental need in Treg therapy development and offered a clinically compatible methodology for future Treg therapy imaging in humans.

Applying this approach, we also showed that Treg trafficking to skin grafts was regulated by the presence of recipient Gr-1⁺ innate immune cells.

Now available in Molecular Therapy – Methods Clinical Development. 

#celltherapy #transplantation #immunotherapy #imaging #molecularimaging 

• 

• 

..we were scattered (with Rico and Qi on the other side of the planet)

BUT we still had great FUN!!!

We are so proud of Ines for these two excellent talks about her PhD work and about the important role of technologists in Nuclear Medicine.

• 

• 

in vivo PET tracking using human NIS as a reporter gene and employing already available radiotracers

(i) enables accurate quantification of CAR-T tumour retention and

(ii) is not damaging the therapeutic cells.

Now available in Molecular Therapy: https://lnkd.in/dTQT2Me 

#celltherapy #cancerresearch #immunotherapy #immunooncology #imaging #molecularimaging #PET

Great work by Candice, Madeleine and Adeel reviewing and explaining how non-invasive reporter gene imaging can aid the development and clinical translation of cell-based therapies. We describe the underlying principles governing non-invasive in vivo long-term cell tracking in the preclinical and clinical settings, including available imaging technologies, reporter genes, and imaging agents as well as pitfalls related to experimental design.(https://doi.org/10.1016/j.ymthe.2020.03.016)

…to Laura for successfully passing her PhD viva!

We might be in lockdown but nothing can stop the FruhwirthGroup…

Foremost, Many Congratulations to Madeleine who did a fantastic job authoring this paper!

We explain how in vivo imaging can aid the development of molecular and cell-based anti-cancer immunotherapies. We describe the principles of imaging host T-cells and adoptively transferred therapeutic T-cells as well as the value of traceable cancer cell models in immunotherapy development. Our emphasis is on in vivo cell tracking methodology, including important aspects and caveats specific to immunotherapies.